Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors-Reference-Cited by-同舟云学术

Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

Published:2021-03-20 Issue:3 Volume:27 Page:340-350
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Jiménez‐Yuste Victor¹^ORCID,Auerswald Günter²,Benson Gary³,Dolan Gerry⁴,Hermans Cedric⁵,Lambert Thierry⁶,Ljung Rolf⁷^ORCID,Morfini Massimo⁸^ORCID,Santagostino Elena⁹^ORCID,Zupančić Šalek Silva¹⁰¹¹¹²

Affiliation:

1. Hospital Universitario La Paz Unidad de Coagulopatías Servicio de Hematología Autonoma University Madrid Spain

2. Klinikum Bremen‐Mitte Professor Hess Children's Hospital Bremen Germany

3. Haemophilia and Thrombosis Centre Belfast City Hospital Belfast UK

4. Centre for Haemostasis and Thrombosis St Thomas' Hospital London UK

5. Haemostasis and Thrombosis Unit Division of Haematology Cliniques Universitaires Saint‐Luc Brussels Belgium

6. Hemophilia Care Center Bicêtre AP‐HP Hospital and Faculté de Médecine Paris XI Paris France

7. Department of Clinical Sciences Lund – Paediatrics Lund University Lund Sweden

8. Italian Association of Haemophilia Centres Florence Italy

9. Fondazione IRCCS Cá Granda Maggiore Hospital Policlinico Angelo Bianchi Bonomi Haemophilia and Thrombosis Center Milan Italy

10. Unit for Haemostasis, Thrombosis and Benign Diseases of Haematopoietic System Division of Haematology Department of Internal Medicine University Hospital Centre Zagreb Zagreb Croatia

11. Medical School University of Zagreb Zagreb Croatia

12. Faculty of Medicine Osijek J Strossmayer University of Osijek Osijek Croatia

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14167

Reference75 articles.

1. Novel therapies and current clinical progress in hemophilia A

2. The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody

3. Practical aspects of extended half-life products for the treatment of haemophilia

4. Current and emerging factor VIII replacement products for hemophilia A

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haemophilia B in Algeria: Realities and therapeutic perspectives;Haemophilia;2023-07-19

2. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance;HemaSphere;2023-06

3. Fitusiran prophylaxis in severe haemophilia without inhibitors;The Lancet Haematology;2023-05

4. Antithrombin-lowering in hemophilia: a closer look at fitusiran;Research and Practice in Thrombosis and Haemostasis;2023-05

5. From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A;Biomedical Papers;2023-03-15